New drug combo tested to shrink breast tumors before surgery
NCT ID NCT07189884
Summary
This study is testing whether a combination of three drugs—pyrotinib, darcilib, and standard hormone therapy—can shrink tumors in patients with a specific type of breast cancer (HR-positive, HER2-low) before they have surgery. The goal is to see if this approach helps control the disease. The study will enroll 33 women with locally advanced breast cancer who are planning to have surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER (LABC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.